Drugs / Anti-CD19 IL-10/IL15 CAR-NK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06614270 | Jan 2025 → Jan 2026 overdue | Sjogren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, antiphospholipid syndrome, idiopathic inflammatory myopathy +2 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD19 IL-10/IL15 CAR-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614270 ↗ |
| Modality | Cell therapy | “Anti-CD19 IL-10/IL15 CAR-NK cells” NCT06614270 ↗ |
| Target | CD19 | “Anti-CD19 IL-10/IL15 CAR-NK cells” NCT06614270 ↗ |